从2020年马来西亚SARS-Cov-2发病机制、诊断和治疗情况看

Y. Wada, Z. Abdul Rahman, M. S. Kaware, Suwaiba Muhammad Ladan
{"title":"从2020年马来西亚SARS-Cov-2发病机制、诊断和治疗情况看","authors":"Y. Wada, Z. Abdul Rahman, M. S. Kaware, Suwaiba Muhammad Ladan","doi":"10.47430/ujmr.2162.002","DOIUrl":null,"url":null,"abstract":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus (CoV) that emerged from China causing diseases known as COVID-19, mainly involves the respiratory system. It has ravaged through most of the world causing death in huge numbers. CoVs are zoonotic as they are transferred from animals to humans. Several animals have been suggested to be the host for SARS-CoV-2 ranging from bats, camels and pigs. The presence of a type 1 transmembrane glycoprotein called spike protein is responsible for CoVs’ ability to penetrate the host’s tissues. The immune response elicited during the proliferation of SARS-CoV-2 is most largely dependent on the macrophages, dendritic cells, T-cells and the human epithelial cells which determine the aftermath and lodging of chemokines and cytokines. The RT-qPCR is the preferred test for the confirmation of the disease although several Rapid Diagnostic Tests are also in use. Remdesivir, favilavir, niclosamide and ciclesonide are promising drugs under clinical trial or research to manage COVID-19. Several vaccines are also under clinical trial phase to mitigate the effect of COVID-19. Malaysia had its index case on the January 24th, 2020 and since then, Malaysia handling of the pandemic have been superb, well planned out and worthy of emulation from other countries. They have carried out an unprecedented number of tests surpassing any other country in the region. Keywords: diagnosis, Malaysia, pathogenesis, Sars-CoV-2, COVID-19, treatment.","PeriodicalId":23463,"journal":{"name":"UMYU Journal of Microbiology Research (UJMR)","volume":"38 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An Insight into the Pathogenesis, Diagnosis and Treatment of SARS-Cov-2 with a Synopsis of Situation in Malaysia during the 2020 Outbreak\",\"authors\":\"Y. Wada, Z. Abdul Rahman, M. S. Kaware, Suwaiba Muhammad Ladan\",\"doi\":\"10.47430/ujmr.2162.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus (CoV) that emerged from China causing diseases known as COVID-19, mainly involves the respiratory system. It has ravaged through most of the world causing death in huge numbers. CoVs are zoonotic as they are transferred from animals to humans. Several animals have been suggested to be the host for SARS-CoV-2 ranging from bats, camels and pigs. The presence of a type 1 transmembrane glycoprotein called spike protein is responsible for CoVs’ ability to penetrate the host’s tissues. The immune response elicited during the proliferation of SARS-CoV-2 is most largely dependent on the macrophages, dendritic cells, T-cells and the human epithelial cells which determine the aftermath and lodging of chemokines and cytokines. The RT-qPCR is the preferred test for the confirmation of the disease although several Rapid Diagnostic Tests are also in use. Remdesivir, favilavir, niclosamide and ciclesonide are promising drugs under clinical trial or research to manage COVID-19. Several vaccines are also under clinical trial phase to mitigate the effect of COVID-19. Malaysia had its index case on the January 24th, 2020 and since then, Malaysia handling of the pandemic have been superb, well planned out and worthy of emulation from other countries. They have carried out an unprecedented number of tests surpassing any other country in the region. Keywords: diagnosis, Malaysia, pathogenesis, Sars-CoV-2, COVID-19, treatment.\",\"PeriodicalId\":23463,\"journal\":{\"name\":\"UMYU Journal of Microbiology Research (UJMR)\",\"volume\":\"38 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"UMYU Journal of Microbiology Research (UJMR)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47430/ujmr.2162.002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"UMYU Journal of Microbiology Research (UJMR)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47430/ujmr.2162.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)是从中国出现的新型冠状病毒(CoV),引起的疾病被称为COVID-19,主要涉及呼吸系统。它在世界大部分地区肆虐,造成大量死亡。冠状病毒是人畜共患的,因为它们从动物转移到人类。有几种动物被认为是SARS-CoV-2的宿主,包括蝙蝠、骆驼和猪。一种被称为刺突蛋白的1型跨膜糖蛋白的存在是冠状病毒穿透宿主组织的能力的原因。在SARS-CoV-2增殖过程中引发的免疫反应在很大程度上依赖于巨噬细胞、树突状细胞、t细胞和人上皮细胞,它们决定了趋化因子和细胞因子的后果和归宿。RT-qPCR是确认该疾病的首选检测方法,尽管也在使用几种快速诊断检测方法。在临床试验或研究中,瑞德西韦、非韦韦、氯硝柳胺和环来奈德是治疗COVID-19的有希望的药物。一些疫苗也处于临床试验阶段,以减轻COVID-19的影响。马来西亚于2020年1月24日出现了首例病例,此后,马来西亚对疫情的处理非常出色,计划周密,值得其他国家效仿。他们进行了前所未有的试验,数量超过了该地区的任何其他国家。关键词:诊断、马来西亚、发病机制、新冠肺炎、治疗
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
An Insight into the Pathogenesis, Diagnosis and Treatment of SARS-Cov-2 with a Synopsis of Situation in Malaysia during the 2020 Outbreak
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus (CoV) that emerged from China causing diseases known as COVID-19, mainly involves the respiratory system. It has ravaged through most of the world causing death in huge numbers. CoVs are zoonotic as they are transferred from animals to humans. Several animals have been suggested to be the host for SARS-CoV-2 ranging from bats, camels and pigs. The presence of a type 1 transmembrane glycoprotein called spike protein is responsible for CoVs’ ability to penetrate the host’s tissues. The immune response elicited during the proliferation of SARS-CoV-2 is most largely dependent on the macrophages, dendritic cells, T-cells and the human epithelial cells which determine the aftermath and lodging of chemokines and cytokines. The RT-qPCR is the preferred test for the confirmation of the disease although several Rapid Diagnostic Tests are also in use. Remdesivir, favilavir, niclosamide and ciclesonide are promising drugs under clinical trial or research to manage COVID-19. Several vaccines are also under clinical trial phase to mitigate the effect of COVID-19. Malaysia had its index case on the January 24th, 2020 and since then, Malaysia handling of the pandemic have been superb, well planned out and worthy of emulation from other countries. They have carried out an unprecedented number of tests surpassing any other country in the region. Keywords: diagnosis, Malaysia, pathogenesis, Sars-CoV-2, COVID-19, treatment.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Molecular Characterization of Agents of Cutaneous Leishmaniasis in Dutsin-Ma Local Government Area of Katsina State, Northwestern, Nigeria Bio-Prospecting Xylose-Utilizing, Exopolysaccharide (EPS)-Producing Bacteria and EPS Quantification through Submerged Fermentation using Xylose as the Major Carbon Source Optimization of Growth Response Parameters, Screening and Molecular Detection of Pesticide Degradation Genes in Bacterial Isolates from Agricultural Soils Comparative Effect of Breast Milk and Infant Formulae on Neonatal Gut Microbiome within Katsina Metropolis Occurrence of Antibiotic Resistant Salmonella and Shigella in Diarrheal cases Resulting from a Common Source Consumption of Contaminated Water
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1